177Lu-EB-FAPI

N/A

Report date: 2025/09/24 14:01:30

Base Information

Drug Name177Lu-EB-FAPI
Drug Alias Name177Lu-Fibroblast activation protein inhibitorPRRT with 177Lu-EB-FAPI177Lu-EB-FAPI
ClassificationRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Lutetium > 177LuRadiation-emitting products > Radionuclide Drug Conjugates
Mechanisms of ActionFibroblast activation protein alpha inhibitorsRadionuclide imaging enhancers
TargetsProlyl endopeptidase FAP
Therapy Area/IndicationsPancreatic NeoplasmsCholangiocarcinomaCarcinoma, Pancreatic Ductal
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryFranceMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesZhejiang University
China Registration ClassN/A

Develop Information

Active CompaniesInstitut CurieZhejiang University
Inactive CompaniesN/A
Active IndicationsPancreatic NeoplasmsCholangiocarcinomaCarcinoma, Pancreatic Ductal
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A